Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$65.68 USD

65.68
3,456,884

-1.42 (-2.12%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (59 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.

OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.

Sanghamitra Saha headshot

5 Top Stocks Likely to Beat Earnings Estimates

by Sanghamitra Saha

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Coty (COTY), BJ's Restaurants (BJRI), DexCom (DXCM), Livent (LTHM) and D.R. Horton (DHI).

DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

DexCom (DXCM) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 54.55% and 4.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Toyota, Deere, Starbucks, AbbVie and DexCom

by Zacks Equity Research

Toyota, Deere, Starbucks, AbbVie and DexCom are included in this Analyst Blog.

Sheraz Mian headshot

Q2 Earnings Season Scorecard and Analyst Reports for Toyota, Deere & Starbucks

by Sheraz Mian

Today's Research Daily features a real-time update on the Q2 earnings season, in addition to featuring updated reports on Toyota Motor(TM), Deere & Company (DE) and Starbucks (SBUX).

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and DexCom (DXCM) have performed compared to their sector so far this year.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.

DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed the most recent trading day at $130.60, moving -0.04% from the previous trading session.

Benjamin Rains headshot

3 Highly-Ranked Large Cap Stocks to Buy Before Earnings for Big Upside

by Benjamin Rains

Exploring three highly-ranked large-cap stocks--Honeywell, DexCom, and NextEra Energy--that investors might want to buy before their upcoming earnings releases for both near-term and long-term upside.

Select Medical (SEM) Expects Q2 Adjusted EBITDA to Jump 21% Y/Y

by Zacks Equity Research

Select Medical's (SEM) strong second-quarter 2023 guidance highlights improving performance in all four segments.

NextGen (NXGN) Settles Misrepresentation Allegations for $31M

by Zacks Equity Research

NextGen (NXGN) settles accusations of software fraud and anti-kickback violations for $31M. However, the company denies any wrongdoing.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Here is Why Growth Investors Should Buy DexCom (DXCM) Now

by Zacks Equity Research

DexCom (DXCM) could produce exceptional returns because of its solid growth attributes.

Select Medical (SEM) Up 21% Year to Date: More Room to Run?

by Zacks Equity Research

Select Medical (SEM) is well-poised for growth on the back of improved patient volumes, an expanding healthcare portfolio and solid cash-generating abilities.

DexCom (DXCM) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

DexCom (DXCM) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, DexCom (DXCM) closed at $133.98, marking a +0.23% move from the previous day.

AngioDynamics (ANGO) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in fourth-quarter fiscal 2023.

3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.